Wegovy Pill vs Foundayo Pill: Comparison, Price and Side Effects (2026)
Prescriptions, price, side effects, weight loss, access and the emerging battle for the oral obesity market
Updated: September 6, 2026 | U.S. market data: September 2026
What are oral GLP-1 pills?
Prescription tracker
Price and affordability
Wegovy pill vs Foundayo
Weight-loss evidence
Side effects and safety
Administration and convenience
Market trajectory
How patients should compare them
Frequently asked questions
What Are Oral GLP-1 Weight-Loss Pills?
GLP-1 receptor agonists have transformed obesity treatment, but the best-known medicines were initially injectable. Oral formulations are now creating a new competitive segment aimed at people who prefer a tablet to an injection.
Two major oral obesity medicines are now competing in the United States: Wegovy pill (oral semaglutide) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly.
Wegovy pill became broadly available in the United States on January 5, 2026. Foundayo was approved by the FDA on April 1, 2026 and became commercially available in April.
These products are related through their GLP-1 mechanism, but they are not the same drug. Semaglutide is a peptide GLP-1 receptor agonist, whereas orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist.
Oral GLP-1 Prescription Tracker: September 2026
The latest oral GLP-1 tracker reported by Fierce Pharma shows that both products continue to establish new prescription highs.
| Metric | Wegovy Pill | Foundayo |
|---|---|---|
| Active ingredient | Semaglutide | Orforglipron |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Weekly U.S. prescriptions | ~181,000 | ~44,000 |
| Latest weekly change | +3% | +8% |
| U.S. launch | January 2026 | April 2026 |
| Current position | Early market leader | Fast-growing challenger |
↔ Swipe the table sideways to see all columns on mobile.
According to the September 4 Fierce Pharma update, IQVIA data cited by Citi showed approximately 181,000 weekly prescriptions for Wegovy pill and 44,000 for Foundayo. Wegovy grew about 3% week over week, while Foundayo grew approximately 8%. Source: Fierce Pharma
Wegovy Pill vs Foundayo: Price and Affordability
Price is likely to become one of the most important variables in the oral GLP-1 race. Unlike a simple list-price comparison, however, the actual amount a patient pays can vary substantially depending on insurance coverage, eligibility for manufacturer savings programs, dose and pharmacy.
Current self-pay pricing
| Product / dose | Current U.S. self-pay price | Important qualification |
|---|---|---|
| Wegovy pill 1.5 mg | $149/month | Starter dose |
| Wegovy pill 4 mg | $199/month | Standard offer after the temporary $149 promotion ended |
| Wegovy pill 9 mg | $299/month | Higher dose |
| Wegovy pill 25 mg | $299/month | Highest oral dose |
| Foundayo 0.8 mg | $149/month | Starting dose |
| Foundayo 2.5 mg | $149/month | Temporary promotional price through Dec. 31, 2026 |
| Foundayo 5.5 mg | $199/month | Temporary promotional price through Dec. 31, 2026 |
| Foundayo 9 mg | $299/month | Current self-pay offer |
| Foundayo 14.5 mg | $299/month | Self-pay Journey Program; refill timing conditions apply |
| Foundayo 17.2 mg | $299/month | Self-pay Journey Program; refill timing conditions apply |
↔ Swipe the table sideways to see all columns on mobile.
Novo Nordisk's current price guide lists Wegovy pill at $149/month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg under its self-pay offer. Eligible commercially insured patients may pay as little as $25/month through the Wegovy savings offer. NovoCare price guide.
Lilly's current Foundayo pricing shows $149/month for 0.8 mg and, under a temporary promotion, 2.5 mg; $199 for 5.5 mg; and $299 for 9 mg, 14.5 mg and 17.2 mg under its current self-pay offers. Eligible commercially insured patients with coverage may pay as little as $25/month. Lilly Foundayo coverage and savings.
Which pill is cheaper?
At the starting-dose level, the two medicines are remarkably close: both have a current advertised self-pay entry point of approximately $149 per month.
At higher doses, the comparison also converges: Wegovy pill is $299/month at 9 mg and 25 mg under Novo Nordisk's current self-pay offer, while Foundayo's current offers reach $299/month at 9 mg and the two highest doses.
Therefore, price alone may not determine the winner. Insurance coverage, savings eligibility, dose required, tolerability and effectiveness may matter more than the headline price.
Wegovy Pill vs Foundayo: Head-to-Head Overview
| Feature | Wegovy Pill | Foundayo |
|---|---|---|
| Company | Novo Nordisk | Eli Lilly |
| Drug | Semaglutide | Orforglipron |
| Drug class | Peptide GLP-1 receptor agonist | Small-molecule GLP-1 receptor agonist |
| Administration | Once daily | Once daily |
| Food restrictions | Specific administration requirements | Can be taken with or without food |
| Water restrictions | Specific water-related administration instructions | No special water restriction |
| Starting self-pay price | From $149/month | From $149/month |
| Higher-dose self-pay price | Up to $299/month | Up to $299/month under current offers |
| Commercial insurance savings | Potentially as little as $25/month for eligible patients | Potentially as little as $25/month for eligible patients |
| Key commercial advantage | Earlier launch and powerful Wegovy brand | Simpler administration and Lilly obesity franchise |
↔ Swipe the table sideways to see all columns on mobile.
How Much Weight Can Patients Lose?
Wegovy Pill
The pivotal OASIS 4 trial evaluated once-daily oral semaglutide 25 mg in adults with overweight or obesity without diabetes.
In the trial, mean weight loss was approximately 13.6% regardless of treatment discontinuation and approximately 16.6% under the trial's treatment-regimen estimand when assuming patients remained on treatment.
These findings formed the basis for FDA approval of oral Wegovy for chronic weight management. New England Journal of Medicine: OASIS 4.
Foundayo
In ATTAIN-1, participants receiving the highest dose of Foundayo who remained on treatment lost an average of approximately 12.4% of body weight, compared with approximately 0.9% with placebo. The treatment-policy analysis showed approximately 11.1% weight loss with Foundayo versus 2.1% with placebo.
Eli Lilly reported an average loss of approximately 27 pounds at the highest dose. Eli Lilly: Foundayo launch and clinical data.
Wegovy Pill vs Foundayo: Side Effects
For many patients, tolerability may matter as much as weight-loss efficacy. Both medicines act on GLP-1 pathways, and gastrointestinal symptoms are among the most important practical limitations.
Common Wegovy pill side effects
The current U.S. Wegovy labeling lists the following common adverse reactions occurring in at least 5% of treated patients:
Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, headache, dizziness, fatigue, abdominal distension, belching, flatulence, gastroesophageal reflux disease and hair loss.
The label notes that adverse-event rates from different clinical trials cannot be directly compared between products because trials vary in design and patient populations. Current Wegovy labeling at DailyMed.
Common Foundayo side effects
Foundayo's most commonly reported adverse reactions include:
Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, belching, gastroesophageal reflux disease, flatulence and hair loss.
In pooled placebo-controlled weight-management trials, gastrointestinal adverse reactions occurred in 60% of patients receiving 5.5 mg, 68% receiving 9 mg and 69% receiving 17.2 mg, compared with 37% of placebo-treated patients.
The incidence of nausea, vomiting and diarrhea was higher during dose escalation and generally decreased over time. About 3% to 6% of patients discontinued Foundayo because of gastrointestinal adverse reactions, compared with 0.7% receiving placebo. Foundayo prescribing information.
| Side-effect category | Wegovy Pill | Foundayo |
|---|---|---|
| Nausea | Common | Very common; 26% at 5.5 mg, 34% at 9 mg, 35% at 17.2 mg in pooled trials |
| Constipation | Common | Common; 20% at 5.5 mg, 27% at 9 mg, 24% at 17.2 mg |
| Diarrhea | Common | Common; 21% at 5.5 mg, 23% at 9 mg, 25% at 17.2 mg |
| Vomiting | Common | 13% at 5.5 mg, 21% at 9 mg, 24% at 17.2 mg |
| Abdominal pain | Common | 13%–14% across the listed doses |
| Indigestion / dyspepsia | Common | 12%–16% across the listed doses |
| Heartburn / GERD | Common | 6%–7% across the listed doses |
| Hair loss | Listed among common adverse reactions | Reported in approximately 4%–5% at the studied doses |
↔ Swipe the table sideways to see all columns on mobile.
Important: The percentages in the table are not a head-to-head comparison. Foundayo figures come from its pooled placebo-controlled trials, while the Wegovy label summarizes adverse reactions across its clinical program.
Serious Warnings: What Patients Need to Know
Neither product should be viewed as a simple cosmetic weight-loss tablet. Both have important warnings and contraindications.
Thyroid C-cell tumor warning
Both semaglutide and orforglipron carry a boxed warning concerning thyroid C-cell tumors based on findings in rodents. The human relevance is unknown. Both products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Severe gastrointestinal problems
Severe gastrointestinal reactions can occur. Persistent or severe stomach symptoms should be evaluated by a healthcare professional.
Dehydration and kidney problems
Persistent vomiting or diarrhea can cause dehydration, which can contribute to kidney problems.
Pancreatitis
Pancreatitis is an important warning for GLP-1 therapies. Severe persistent abdominal pain, particularly pain that may radiate to the back, warrants urgent medical evaluation.
Gallbladder disease
GLP-1 medicines can also be associated with gallbladder-related problems, including gallstones and cholecystitis.
Delayed gastric emptying and other medication effects
Because GLP-1 therapies affect gastric emptying, they can affect the absorption of some oral medicines. Foundayo's prescribing information specifically warns about this interaction and also contains drug-specific interaction guidance.
Foundayo additionally carries specific reproductive guidance concerning oral contraceptives after initiation and dose escalation. Foundayo full prescribing information.
Administration: Where Foundayo Has a Practical Advantage
The most obvious differentiator between the two oral products is not price but how the tablet fits into daily life.
Foundayo can be taken once daily with or without food and at any time of day. This is a major convenience advantage because it reduces the number of administration rules patients need to remember.
Wegovy pill also provides the convenience of a tablet instead of an injection, but oral semaglutide has more specific administration requirements concerning fasting, timing and water.
| Practical factor | Wegovy Pill | Foundayo |
|---|---|---|
| Needle-free | Yes | Yes |
| Once daily | Yes | Yes |
| Can take with food | No; specific fasting instructions apply | Yes |
| Special water requirements | Yes | No |
| Any-time-of-day flexibility | More limited | Yes |
↔ Swipe the table sideways to see all columns on mobile.
For patients who find traditional oral semaglutide administration inconvenient, Foundayo's simpler routine may become an important competitive differentiator.
Why Wegovy Pill Has a Large Early Lead
Wegovy's current prescription lead reflects a combination of timing, brand recognition and the strength of Novo Nordisk's existing obesity franchise.
The pill launched in January 2026, approximately three months before Foundayo. Novo already had years of consumer and physician familiarity with the Wegovy name.
Novo Nordisk also reported rapid early uptake after launch and broad distribution across U.S. pharmacies and telehealth channels.
The latest prescription data show that the lead remains substantial, but the percentage growth rate of Foundayo deserves attention.
Why Foundayo Could Gain Market Share
Foundayo has several potential commercial advantages beyond being the second entrant.
First, administration is simpler. The tablet can be taken with or without food and without special water restrictions.
Second, Lilly already owns a major obesity franchise. Zepbound gives the company prescriber relationships, obesity-market experience and a large existing customer base.
Third, access is improving. Lilly's savings and coverage programs are designed to reduce the cost barrier for eligible patients.
Fourth, the price is competitive. The current self-pay entry point of $149/month is essentially the same as Wegovy pill.
Therefore, Foundayo does not need to beat Wegovy on price to compete. It can compete through a combination of convenience + efficacy + tolerability + access + brand positioning.
How Patients Should Compare Wegovy Pill and Foundayo
There is no universally "best" oral GLP-1. The better choice for one patient may be different for another.
1. Price
Compare the actual expected out-of-pocket cost, not just the manufacturer's headline price. Insurance coverage, deductibles, savings-card eligibility and dose can materially change the final cost.
2. Administration
Patients with demanding schedules may place a high value on Foundayo's ability to be taken without food or water restrictions.
3. Weight-loss goal
Consider the amount of weight loss likely to be clinically meaningful for the individual. Trial results should be interpreted within the context of each study rather than as a direct ranking.
4. Tolerability
A drug that produces excellent results but causes persistent nausea, constipation, diarrhea or vomiting may not be the most practical long-term option.
5. Existing medical conditions
The prescribing information, contraindications and potential interactions must be considered, particularly in people taking multiple medicines or with gastrointestinal, endocrine, renal, pancreatic or gallbladder conditions.
6. Long-term treatment
Obesity is generally a chronic disease, so affordability, adherence and tolerability over months and years may ultimately matter more than the initial response during the first few months.
What Investors Should Watch
The oral GLP-1 market is moving from a launch story to an execution story. Investors should increasingly focus on:
New prescriptions: Is Foundayo continuing to gain faster than Wegovy pill?
Refill persistence: Are patients staying on therapy?
Gross-to-net pricing: How much revenue remains after rebates and discounts?
Insurance coverage: Is payer access improving?
Discontinuation rates: Does tolerability limit long-term use?
Conversion: Are patients moving from injectable GLP-1 therapies to pills?
New competitors: How quickly will next-generation oral and multi-agonist medicines enter the market?
Bottom Line
Wegovy pill is winning the oral GLP-1 race today. With approximately 181,000 weekly prescriptions versus roughly 44,000 for Foundayo, Novo Nordisk has established a substantial early lead.
But the story is not finished.
Foundayo is growing faster on a weekly percentage basis, offers a simpler dosing routine, and is priced competitively. Its current self-pay pricing begins at approximately $149/month, essentially matching the entry price of Wegovy pill.
The side-effect profiles are also broadly recognizable as GLP-1-class effects, with gastrointestinal symptoms dominating both products' safety profiles. The practical winner may therefore depend less on a dramatic difference in side effects and more on individual tolerability, administration convenience, insurance coverage and sustained adherence.
For patients, the most important question is not simply "Which pill is stronger?" It is: "Which treatment provides a meaningful benefit that I can afford, tolerate and consistently take long term?"
For investors, the key question is different: Can Foundayo's faster prescription growth close a gap that currently remains more than four-to-one in Wegovy's favor?
Frequently Asked Questions
How much does the Wegovy pill cost in 2026?
Current NovoCare self-pay pricing lists $149/month for 1.5 mg, $199/month for 4 mg and $299/month for 9 mg and 25 mg. Eligible commercially insured patients may qualify to pay as little as $25/month under the manufacturer savings offer.
How much does Foundayo cost?
Current Lilly self-pay offers start at $149/month. The listed current offers include $149 for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg and 17.2 mg, subject to eligibility and program conditions.
Which is cheaper, Wegovy pill or Foundayo?
At the starting dose, the current advertised self-pay price is approximately $149/month for both. At higher doses, both products can reach approximately $299/month under their current manufacturer offers. Actual patient cost depends on insurance and eligibility.
What are the most common side effects of Wegovy pill?
Common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, headache, fatigue, abdominal distension, belching, reflux, flatulence and hair loss.
What are the most common side effects of Foundayo?
Common adverse reactions include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal distension, fatigue, belching, reflux, flatulence and hair loss.
Is Foundayo easier to take than Wegovy pill?
For many patients, it may be. Foundayo can be taken with or without food and without special water restrictions, whereas oral semaglutide has more specific administration instructions.
Which causes more nausea?
There is no scientifically valid head-to-head answer from the available pivotal obesity trials. Foundayo's pooled trials show nausea rates of 26% at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg, but these percentages should not be directly compared with Wegovy trial results because the studies differ.
Can GLP-1 side effects improve over time?
They often become less prominent after treatment initiation and dose escalation. Foundayo's prescribing information specifically notes that nausea, vomiting and diarrhea were more common during dose escalation and decreased over time. Individual experiences vary.
Do Wegovy pill and Foundayo have serious warnings?
Yes. Important warnings include the boxed warning concerning thyroid C-cell tumors, as well as potential serious gastrointestinal problems, dehydration and kidney injury, pancreatitis, gallbladder problems and other product-specific risks. Patients should consult the full prescribing information.
Is Wegovy pill better than Foundayo?
Not conclusively. Wegovy pill currently has the stronger commercial position, but separate clinical trials cannot establish superiority. A head-to-head randomized trial would provide stronger evidence.
Sources and Further Reading
- Fierce Pharma — Oral GLP-1 prescription tracker
- NovoCare — Wegovy Price Guide
- Novo Nordisk — Wegovy pill U.S. launch and pricing
- DailyMed — Current Wegovy prescribing information
- NEJM — OASIS 4 oral semaglutide trial
- Eli Lilly — Foundayo coverage and savings
- DailyMed — Foundayo prescribing information
- Eli Lilly — Foundayo launch and ATTAIN clinical data
Medical disclaimer: This article is for educational purposes and is not medical advice. Wegovy and Foundayo are prescription medicines with contraindications, warnings, drug interactions and potential serious adverse effects. Product prices, savings programs, insurance coverage and eligibility can change. Patients should consult a qualified healthcare professional and review the current prescribing information before treatment.
.png)
Comments